Thus, with deletion, mutation, or genetic polymorphisms of CDKN2A, the expression and effectiveness of p16INK4A and p14ARF tumor suppressors are decreased, leading to deregulation of cell proliferation and cancer development [25, 26]. This evidence concerns the gene CDKN2A and cancer.